[
  {
    "text": "physician participation statewide with only 234 physicians and APRN’s having issued one or more cards in 2023. 2. The requirement of an in-person physician-patient visit to establish a bona-fide relationship with a card issuer is burdensome. 3. The uninsured and uncontrolled cost of a medical cannabis card can range from $100 to $300 omit the $38.50 state fee, depending on the provider and island. 4. With limited physician participation, mandatory in-person visits, and high cost of entry, the program has become unaffordable and unattractive. 5. The next largest impacting factor has been the explosion of viable cannabis products that are being",
    "number": 100.0,
    "filename": "HB302_TESTIMONY_HLT_01-29-25_.PDF.txt",
    "document_type": "testimony"
  },
  {
    "text": "statewide with only 234 physicians and APRN’s having issued one or more cards in 2023. 2. The requirement of an in-person physician-patient visit to establish a bona-fide relationship with a card issuer is burdensome. 3. The uninsured and uncontrolled cost of a medical cannabis card can range from $100 to $300 omit the $38.50 state fee, depending on the provider and island. 4. With limited physician participation, mandatory in-person visits, and high cost of entry, the program has become unaffordable and unattractive. 5. The next largest impacting factor has been the explosion of viable cannabis products that are being sold under",
    "number": 300.0,
    "filename": "HB302_TESTIMONY_HLT_01-29-25_.PDF.txt",
    "document_type": "testimony"
  },
  {
    "text": "234 physicians and APRN’s having issued one or more cards in 2023. 2. The requirement of an in-person physician-patient visit to establish a bona-fide relationship with a card issuer is burdensome. 3. The uninsured and uncontrolled cost of a medical cannabis card can range from $100 to $300 omit the $38.50 state fee, depending on the provider and island. 4. With limited physician participation, mandatory in-person visits, and high cost of entry, the program has become unaffordable and unattractive. 5. The next largest impacting factor has been the explosion of viable cannabis products that are being sold under the guise of",
    "number": 38.5,
    "filename": "HB302_TESTIMONY_HLT_01-29-25_.PDF.txt",
    "document_type": "testimony"
  },
  {
    "text": "hemp products and chapter 329D ; and [ (7) ] (8) For any other expenditure necessary, consistent with this chapter and chapter 329D, to implement medical cannabis registry and regulation programs.\" SECTION 15 . There is appropriated out of the medical cannabis registry and regulation special fund the sum of $750,000 or so much thereof as may be necessary for fiscal year 2025-2026 and the same sum or so much thereof as may be necessary for fiscal year 2026-2027 for the department of the attorney general to enforce, and mitigate nuisances relating to, illegal cannabis and hemp products and chapter 329D,",
    "number": 750000.0,
    "filename": "HB302_CD1_.HTM.txt",
    "document_type": "document"
  },
  {
    "text": "dispensary beginning July 1, 2025, rather than January 1, 2027; (7) Authorizing expenditures from the Medical Cannabis Registry and Regulation Special Fund to fund programs for the mitigation and abatement of nuisances related to illegal cannabis and hemp products as well as medical cannabis dispensaries; (8) Inserting an appropriation of $750,000 from the Medical Cannabis Registry and Regulation Special Fund for the mitigation and abatement of nuisances related to illegal cannabis and hemp products and medical cannabis dispensaries, including the establishment of positions; (9) Prohibiting the cultivation of cannabis without a license issued by the Department of Health beginning January 1,",
    "number": 750000.0,
    "filename": "HB302_CD1_CCR255_.htm.txt",
    "document_type": "committee_hearing"
  },
  {
    "text": "include- 1. Limited physician participation statewide with only 237 physicians and APRN’s registered as of December 2024. 2. The requirement of an in-person physician-patient visit to establish a bona-ﬁde relationship with a card issuer is burdensome. 3. The uninsured and uncontrolled cost of a medical cannabis card can range from $100 to $300 omit the $38.50 state fee, depending on the provider and island. 4. With limited physician participation, mandatory in-person visits, and high cost of entry, the program has become unaffordable and unattractive. LATE *Testimony submitted late may not be considered by the Committee for decision making purposes. \u0010\u0005\u0018 5.",
    "number": 100.0,
    "filename": "HB302_HD1_TESTIMONY_CPC_02-06-25_.PDF.txt",
    "document_type": "testimony"
  },
  {
    "text": "Limited physician participation statewide with only 237 physicians and APRN’s registered as of December 2024. 2. The requirement of an in-person physician-patient visit to establish a bona-ﬁde relationship with a card issuer is burdensome. 3. The uninsured and uncontrolled cost of a medical cannabis card can range from $100 to $300 omit the $38.50 state fee, depending on the provider and island. 4. With limited physician participation, mandatory in-person visits, and high cost of entry, the program has become unaffordable and unattractive. LATE *Testimony submitted late may not be considered by the Committee for decision making purposes. \u0010\u0005\u0018 5. The next",
    "number": 300.0,
    "filename": "HB302_HD1_TESTIMONY_CPC_02-06-25_.PDF.txt",
    "document_type": "testimony"
  },
  {
    "text": "statewide with only 237 physicians and APRN’s registered as of December 2024. 2. The requirement of an in-person physician-patient visit to establish a bona-ﬁde relationship with a card issuer is burdensome. 3. The uninsured and uncontrolled cost of a medical cannabis card can range from $100 to $300 omit the $38.50 state fee, depending on the provider and island. 4. With limited physician participation, mandatory in-person visits, and high cost of entry, the program has become unaffordable and unattractive. LATE *Testimony submitted late may not be considered by the Committee for decision making purposes. \u0010\u0005\u0018 5. The next largest impacting factor",
    "number": 38.5,
    "filename": "HB302_HD1_TESTIMONY_CPC_02-06-25_.PDF.txt",
    "document_type": "testimony"
  },
  {
    "text": "other medications. It should allow telemedicine for medical cannabis. 1 Omboni S, et al. The worldwide impact of telemedicine during COVID-19: current evidence and recommendations for the future. Connect Health. 2022 Jan 4;1:7-35. doi: 10.20517/ch.2021.03. PMID: 35233563; PMCID: PMC7612439. WA , \\\\> 1“, .§\\ L /0 at \", ,l’/ \" $5 ' \"Ore r \\~~ \"\"3 /”/\\*~\\ Proposed Amendment: Allowing Medical Cannabis “Off-Label” Healthcare providers should be able to certify patients with any medical condition — or any debilitating medical condition — for the medical cannabis program. One-fifth of all prescriptions are “off-label,” or for a medical condition other than the",
    "number": 5.0,
    "filename": "HB302_HD2_TESTIMONY_HHS-CPN_03-19-25_.PDF.txt",
    "document_type": "testimony"
  },
  {
    "text": "in decline. It is easier, cheaper [no 329 card required], and faster to get supply from the unregulated/illicit market. Within the dispensary system quality and variety of products continue to increase while prices are going down. For example, Big Island Grown’s RSO is available at the everyday low price of $20 per gram ensuring the most vulnerable patients in need have access to this therapeutic option, as well as $25-$30 quality eighths. Licensing fees have increased [300% for some] while patient numbers continue to decline. Currently there are not enough patient sales to support current licensees to even grow their own",
    "number": 20.0,
    "filename": "HB302_SD1_TESTIMONY_WAM-JDC_04-01-25_.PDF.txt",
    "document_type": "testimony"
  }
]